Blueprint Medicines Corp

Health Care
Biotechnology: Pharmaceutical Preparations
www.blueprintmedicines.com

Earnings Score
Moat Score
Safety Score

Market Cap $6.39B
PE -41
Debt $411.87M
Cash $134.09M
EV $6.67B
FCF -$150.91M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$155.73M
EBIT	-$153.89M
ROE	-46%
ROA	-13%
FCF	-$150.91M
Equity	$342.13M
Growth Stability	1
PE	-41.03
PEG	-4.41K
PB	18.67
P/FCF	-42.34
P/S	11.37
Price/Cash	0.02
Debt/Equity	1.2
Debt/FCF	-2.73
Net Margins	0%
Gross Margins	96%
Op. Margins	-27%
Earnings CAGR	0%
Sales Growth YoY	55%
Sales Growth QoQ	2%
Sales CAGR	50%
FCF CAGR	0%
Equity CAGR	9%
Earnings Stability	0
Earnings Growth YoY	-99%

Earnings Growth QoQ	-101%
Earnings CAGR 5Y	0%
Sales CAGR 5Y	2%
FCF CAGR 5Y	0%
Equity CAGR 5Y	-33%
Earnings CAGR 3Y	41%
Sales CAGR 3Y	41%
Equity CAGR 3Y	-25%
Market Cap	$6.39B
Revenue	$562.12M
Assets	$1.20B
Total Debt	$411.87M
Cash	$134.09M
Shares Outstanding	64.1M
EV	6.67B
Earnings Score	6%
Moat Score	16%
Safety Score	63%
Final Score	28%
Working Capital	451.49M
Current Ratio	2.8
Gross Profit	$542.35M
Shares Growth 3y	3%
Equity Growth QoQ	15%
Equity Growth YoY	10%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

SEC Filings

Direct access to Blueprint Medicines Corp (BPMC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Blueprint Medicines Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Blueprint Medicines Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%

Stability 0%

loading chart...

Blueprint Medicines Corp Discounted Cash Flow

Fully customizable DCF calculator online for Blueprint Medicines Corp.

Years

Calculation mode

= -$1.5B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$151M	-$151M	-$151M	-$151M	-$151M	-$151M	-$151M	-$151M	-$151M	-$151M	-$151M	-$1.5B
DCF		-$137M	-$125M	-$113M	-$103M	-$94M	-$85M	-$77M	-$70M	-$64M	-$58M	-$582M
Value	-$1.5B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-491%	-261%	-691%	-532%	-523%	40%	-358%	-273%	-203%	-13%	0%
ROA	-	-	-	-	-49%	18%	-51%	-41%	-48%	-6%	-13%
ROE	-	-34%	-24%	-56%	-75%	21%	-66%	-108%	-388%	-22%	-46%

Bad Net Margins (0.33%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-0.01	-	-	-	-	-0.84	-0.98	-2.05	-2.73
Debt over Equity	-	-	0	-	-	-	-	0.84	3.38	1.36	1.2
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-2.73)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Neutral Debt/Equity ratio (1.2)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	144%	-23%	108%	49%	1K%	-77%	13%	22%	104%	2%
Earnings YoY growth	-	30%	104%	60%	47%	-190%	-305%	-13%	-9%	-87%	0%
Equity YoY growth	-	48%	193%	-33%	11%	217%	-34%	-47%	-75%	129%	-33%
FCF YoY growth	-	-27%	404%	39%	56%	-231%	-179%	69%	-11%	-56%	0%